gsk-2334470 and navitoclax

gsk-2334470 has been researched along with navitoclax* in 1 studies

Other Studies

1 other study(ies) available for gsk-2334470 and navitoclax

Article	Year
Phosphoinositide-dependent protein kinase 1 is a potential novel therapeutic target in mantle cell lymphoma. Experimental hematology, 2018, Volume: 59 Topics: 3-Phosphoinositide-Dependent Protein Kinases; Aniline Compounds; Cell Line, Tumor; Humans; Indazoles; Lymphoma, Mantle-Cell; Phosphorylation; Proto-Oncogene Proteins c-akt; Pyrimidines; Ribosomal Protein S6 Kinases, 90-kDa; Signal Transduction; Sulfonamides	2018

Article

Year

Phosphoinositide-dependent protein kinase 1 is a potential novel therapeutic target in mantle cell lymphoma.

Experimental hematology, 2018, Volume: 59

Topics: 3-Phosphoinositide-Dependent Protein Kinases; Aniline Compounds; Cell Line, Tumor; Humans; Indazoles; Lymphoma, Mantle-Cell; Phosphorylation; Proto-Oncogene Proteins c-akt; Pyrimidines; Ribosomal Protein S6 Kinases, 90-kDa; Signal Transduction; Sulfonamides

2018